You are here:Home-Conferences-Bootcamp: Post-Approval Economics for New Antibiotics (ASM/ESCMID 2019)

Bootcamp: Post-Approval Economics for New Antibiotics (ASM/ESCMID 2019)

Antibiotic Bootcamps for Developers: Post-Approval Economics for New Antibiotics

ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

3-6 September 2019, Boston

Collaboratively organized by GARDP, CARB-X, REPAIR Impact Fund, JPIMAR and Wellcome Trust


Moderator: Ryan Cirz

Speakers: Kevin Krause (AN2 Therapeutics, U.S. and formerly Achaogen), Craig Lichtenstein (Sana Biotechnology, U.S. and formerly Achaogen), Rolf Wagenaar (CD&E Consulting LLC, U.S.)

Q&A session: Kevin Krause (AN2 Therapeutics, U.S. and formerly Achaogen), Craig Lichtenstein (Sana Biotechnology, U.S. and formerly Achaogen), Rolf Wagenaar (CD&E Consulting LLC, U.S.), Ryan Cirz


  1. Introduction & background (John H. Rex & Ryan Cirz)
  2. Post-Marketing Commitments and Antimicrobial Susceptibility Test Development (Kevin Krause)
  3. Supply Chain Robustness, Inventory Build, and Quality Assurance (Craig Lichtenstein)
  4. Sales and Marketing (Rolf Wagenaar)
  5. Additional Economic Considerations (Kevin Krause)
  6. Questions & answers
2019-11-29T13:11:04+00:00